ArticleJACC. CardioOncology2024

Cardiovascular Eligibility Criteria and Adverse Event Reporting in Combined Immune Checkpoint and VEGF Inhibitor Trials.

Stephen Rankin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.